- Home
- INM vs SONN Comparison
INM vs SONN Comparison
Compare INM & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SONN
- Stock Information
- Founded
- INM 1981
- SONN N/A
- Country
- INM Canada
- SONN United States
- Employees
- INM N/A
- SONN N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- SONN Health Care
- Exchange
- INM Nasdaq
- SONN Nasdaq
- Market Cap
- INM 2.3M
- SONN 2.5M
- IPO Year
- INM N/A
- SONN N/A
- Fundamental
- Price
- INM $1.86
- SONN $1.25
- Analyst Decision
- INM
- SONN Strong Buy
- Analyst Count
- INM 0
- SONN 2
- Target Price
- INM N/A
- SONN $38.00
- AVG Volume (30 Days)
- INM 17.2K
- SONN 45.6K
- Earning Date
- INM 05-13-2025
- SONN 05-13-2025
- Dividend Yield
- INM N/A
- SONN N/A
- EPS Growth
- INM N/A
- SONN N/A
- EPS
- INM N/A
- SONN N/A
- Revenue
- INM $4,832,013.00
- SONN $1,000,000.00
- Revenue This Year
- INM N/A
- SONN $5,376.22
- Revenue Next Year
- INM N/A
- SONN N/A
- P/E Ratio
- INM N/A
- SONN N/A
- Revenue Growth
- INM N/A
- SONN 674.14
- 52 Week Low
- INM $1.81
- SONN $1.22
- 52 Week High
- INM $15.70
- SONN $16.80
- Technical
- Relative Strength Index (RSI)
- INM 23.46
- SONN 35.01
- Support Level
- INM $1.99
- SONN $1.33
- Resistance Level
- INM $2.14
- SONN $1.35
- Average True Range (ATR)
- INM 0.15
- SONN 0.12
- MACD
- INM -0.05
- SONN -0.00
- Stochastic Oscillator
- INM 4.67
- SONN 6.25
Stock Price Comparison Chart: INM vs SONN
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.